Do Billionaires Already Have Anti-Ageing Treatments? Here’s What We Know
Billionaires are investing vast sums in companies studying cellular rejuvenation, gene therapies and medicines that may one day influence how we age. That has prompted an understandable question: do the ultra-wealthy already have access to anti-ageing treatments that everyone else will have to wait for?
It matters because ageing research attracts both genuine scientific ambition and confident claims that can run far ahead of human evidence. Looking younger, feeling more energetic, or receiving expensive testing is not the same as slowing whole-body ageing, preventing several age-related diseases or extending life.
What wealth can buy now
Extreme wealth can provide rapid access to specialists, detailed health assessments, personal support with exercise and nutrition, and more time and resources to address health problems early. These advantages can make a meaningful difference to health and independence over time.
The video also explores the well-established link between income and life expectancy. This is an important distinction: a longer life among wealthier people does not demonstrate the existence of a hidden anti-ageing drug. Earlier prevention, safer living conditions and better access to treatment can create a major advantage without reversing ageing itself.
The gap between promising science and proven treatment
Some medicines are already being used experimentally or off-label in longevity-focused clinics. Rapamycin and metformin are among the best-known examples, while hormones, peptides, NAD treatments and extensive supplement programmes are often marketed under the same broad label. Yet a medicine can be real, prescribed and biologically interesting without being proven to slow ageing in healthy humans.
The video looks at why animal findings, changes in biological-age tests and personal reports are not enough to establish a meaningful anti-ageing effect. It also examines the young-donor-plasma claim, including the FDA’s warning that plasma is not approved for ageing or memory loss and carries genuine risks.
Where the frontier really is
Some of the most ambitious work is moving through early-stage clinical research, including a first-in-human study of partial cellular reprogramming for a serious optic nerve condition. Other companies backed by major investors are pursuing related approaches, but much of this work remains early, targeted to particular diseases or still preclinical.
For adults interested in healthy ageing, the key issue is not whether exciting research exists—it does—but how to tell the difference between a carefully monitored experiment and an established treatment. Watch the video for Dr Deepa’s evidence-based look at what billionaire funding is supporting, what remains uncertain, and the questions worth asking before paying for any treatment described as anti-ageing.